Home » Use of Cannabis as a Response to the Overdose Crisis
Use of Cannabis as a Response to the Overdose Crisis
"The opioid epidemic is a public health crisis that is at least partially driven by harms associated with POM [Prescription Opioid Medication] use. States are passing laws allowing use of MC [Medical Cannabis] and patients are using MC, but currently there is little understanding of how this influences POM use or of MC-related harms. This literature review provides preliminary evidence that states with MC laws have experienced reported decreases in POM use, abuse, overdose, and costs. However, existing evidence is limited by significant methodological shortcomings; so, general conclusions are difficult to draw.
"The use of MC as an alternative to POMs for pain management warrants additional empirical attention as a potential harm reduction strategy. NASEM (2017) recommends more clinical trials to elucidate appropriate MC forms, routes of administration, and combination of products for treating pain, but access to MC products to fully evaluate these questions is challenging due to federal regulations. However, the recently funded National Institutes of Health longitudinal study to research the impacts of MC on opioid use is a critical step in the right direction (National Institute of Health, 2017, Williams, 2017). MCs potential as an alternative pain treatment modality to help mitigate the major public health opioid crisis, could be a missed opportunity if data on safety, efficacy, and outcomes are not collected and explored. Health care practitioners, particularly nurses who are charged with ensuring patient comfort, have a vested interest in providing viable alternatives to POMs when appropriate, as part of an integrative approach to pain management, and must advocate for more research to better understand the public health implications and risks and benefits of such alternatives."
Vyas, Marianne Beare et al. The use of cannabis in response to the opioid crisis: A review of the literature. Nursing Outlook, January-February 2018, Volume 66, Issue 1, 56 - 65.
https://www.ncbi.nlm.nih.gov/p...
www.nursingoutlook.org
Substance:
Prescription Analgesics
Addiction and Dependence
Capital Punishment for Drug Offenses
Cocaine & Crack
Crime, Arrests & Law Enforcement
Dark Net Drug Markets & Cryptomarkets
Diversion of Drugs
Driving and Drugs
Drug Testing (Employment)
Drug Testing (Schools)
Drug Use Prevalence and Trends
Ecstasy (MDMA)
Entheogens & Psychedelics
Gateway Hypothesis
Heroin Assisted Treatment
Injection Drug Use and HIV/AIDS
Injection Drug Use and Race
Mandatory Minimums
Marijuana Policies & Policy Reform
Mental Health Medications (Psychotropics)
Mental Health, Drug Use, Co-Occurring Disorders and Dual Diagnosis
Mushrooms (Psilocybin)
Netherlands vs US
New Psychoactive Substances
Opioid Substitution Treatment
Pregnancy and Substance Use
Prevalence of Substance Use
Prisons and Drugs
Prisons and Jails Overview
Psilocybin (Magic Mushrooms)
Race & Prisons
Recovery and Social Reintegration
Supervised Consumption Facilities and Overdose Prevention Sites
Supply Reduction
Syringe Service and Needle Exchange Programs
Tobacco & Nicotine
Treatment for Substance Use Disorders
Young People and Drugs
Regions Outside the US
Central Asia and Eastern Europe
Copyright © 2020, Common Sense for Drug Policy